Endpoint | Patients achieving endpoint, n/N (%) | |||
---|---|---|---|---|
95% CI | ||||
At week 24 visit | Up to week 24 visit | At end of treatment | Up to end of treatment | |
≥35% spleen volume reduction by MRI | 4/17 (23.5) | 5/23 (21.7) | 4/23 (17.4) | 7/23 (30.4) |
95% CI 6.8–49.9 | 95% CI 5.0–38.8 | |||
≥50% spleen length reduction by physical examination | 9/19 (47.4) | 12/31 (38.7) | 9/31 (29.0) | 12/31 (38.7) |
95% CI 24.4–71.1 | 95% CI 14.2–48.0 | |||
≥50% reduction in MF Quality of Life and Symptom Assessment total symptom score | 7/18 (38.9) | 12/29 (41.4) | 4/29 (13.8) | 12/29 (41.4) |